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A deepened understanding of the cellular and molecular processes in the tumor microenvironment is necessary
for the development of precision immunotherapy (IT). We simultaneously investigated CD3, PDL1, and IDO by
immunohistochemistry in paired biopsies from various organs of 43 metastatic melanoma patients treated with IT
and targeted therapy (TT). Intraindividual biopsies taken after a period of weeks to months demonstrate discordant
results in 30% of the cases. Overlap of IDO and PDL1 increased after therapy. IT only marginally impacted PDL1
expression over time in contrast to TT. Standardized repeated assessments of multiple immune markers in
repeated biopsies will generate detailed insights in melanoma's immune evolution and adaption during therapies
and might be used to support treatment decisions.
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Immunotherapy (IT) has revolutionized the therapeutic land-
scape for advanced melanoma [1–3] and other tumor types.
Multiple antibodies and other medications are under develop-
ment that will widen the treatment options. In order to optimize
IT, a deepened understanding of the cellular and molecular
processes in the tumor microenvironment is mandatory that will
allow a rational selection of the therapeutic tools resulting in
precision IT [4].
Nivolumab and pembrolizumab bind to PD-1 and interrupt
the interaction with its ligands PDL1 and PDL2 that inhibit
antitumor T cell functions. Clinical benefit correlates with the
expression levels of PDL1 in melanoma and other tumors such as
lung carcinomas [5]. PDL1 expression on tumor cells helps to
identify metastatic melanoma patients that achieve a similar
benefit with nivolumab monotherapy than with the Nivo/Ipi
combination therapy. Therefore, PDL1 may be a biomarker of
clinical relevance [6].
Multiple, genetic, and epigenetic mechanisms regulate PDL1
expression levels on tumor cells [7]. In melanoma, PDL1 expression
is enhanced by the presence of interferon-gamma–secreting
lymphocytes in the tumor microenvironment in most cases,
rendering its expression a surrogate for the intratumoral accumula-
tion of T cells [8].Interferon-gamma is also a strong inducer of indoleamin-2,
3-dioxygenase 1 (IDO). This cytosolic heme enzyme is expressed in
various tissues including placenta where it is essential to promote
immune privilege. IDO catabolizes tryptophan to kynurenine and
other metabolites, resulting in tryptophan depletion suppressing
T-cell functions [9].
In melanoma, the presence of IDO has negative prognostic
implications as shown for IDO expression in peritumoral endothelium
cells [10], in the sentinel lymph node [11], in nodal metastases, and for
the kynurenine/tryptophan ratio in the serum [12]. Both PDL1 and
IDO are important drug targets of monoclonal antibodies such as
avelumab (MERCK) or the orally available epacadostat (INCB024360,
Incyte). The combination of IDO inhibitors and an anti-PD1 antibody
Table 1. Patients' Characteristics
Age (Median) 56 (24-83)
Gender
M 23
F 20
Melanoma subtypes
SSM 10
NMM 14
ALM 4
Amel 3
Nev 1
Polyploid 1
UKT 8
UKO 2
Localization before
Subcutaneous 29
Nodal 8
Lung 2
Soft tissue 2
Hepatic 1
Unknown 1
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currently investigated in larger phase III trials [13,14].
There is limited information about the coexpression of IDO1 and
the presence of tumor-infiltrating lymphocytes (TILs) such as T-cells
and the consistency of these features during targeted and/or IT along
with PDL1 expression in human melanoma biopsies. We here report
results on these immune markers in a set of melanoma patients with
multiple metastases and an expanded in silico investigation on these
and other immune markers in the public database “The Cancer
Genome Atlas (TCGA) Melanoma” [15,16].
Patients and Methods
An extensive search in the internal dermatopathology database
(Dermapro®) of the department of dermatology at the University
Hospital of Zurich was performed. Keyword “melanoma”was used in full
text search to identify patients with metastatic melanoma, from which
serial tumor material is available. Clinical data were obtained from the
KISIM electronic patient record of the University Hospital Zurich.
Based on this information, patients with serial melanoma biopsies
before and after immuno- or targeted therapy were included.
Treatments included immunotherapies including both anti–
CTLA-4 and anti–PD-1 molecules and targeted therapies including
BRAF- and MEK-inhibitors as well as chemotherapy and a tyrosine
kinase inhibitor.
Exclusion criteria included insufficient or unavailable tumor
material for staining, insufficient clinical follow-up data, and explicit
refusal of patient data-based research at hospital admission.
Permission for this noninterventional research project was granted
by the relevant authority (ethics committee of the Canton of Zurich,
Switzerland, KEK-ZH-Nr. 2014-0193).
Immunohistochemistry
Formalin-fixed, paraffin-embedded samples from our histopathol-
ogy archive were stained for CD3 in our research laboratory.
Standard automated protocols using a DAKO Autostainer with
Real Detection System Alkaline Phosphatase was used. CD3 staining
was performed using a monoclonal mouse antibody (DAKO,
M7254, clone F7.2.38); heat-mediated antigen retrieval with
EDTA buffer was performed. TRS high buffer was used for
heat-mediated antigene retrieval. Normal human tonsil served as a
positive control.
Stainings for IDO expression as described [10] were performed by
Ines Chevolet (I.C.) in the laboratory of Liève Brochez (L.B.). A
monoclonal mouse antibody (Millipore, clone 10.1) was used in a
standard avidin-biotin-peroxidase protocol (Dako).
PDL1 immunoreactivity was assessed by an immunohistochemical assay
for formalin-fixed, paraffin-embedded tumor specimens that incorporated a
rabbit monoclonal anti-human PDL1 antibody (clone 28-8) and an
automated staining procedure developed by DAKO. Percentage PDL1
expression was scored manually by a qualified pathologist where positive
PDL1 staining was defined as complete circumferential or partial linear
plasma membrane staining of tumor cells [17,18]. Both staining and
analysis for PDL1 expressionwere performed byMosaic Laboratories, Lake
Forest, CA, on behalf of Bristol Myers Squibb.Localization after
Subcutaneous 31
Nodal 5
Soft tissue 4
Bone 1
Ileum 1
Cerebral 1Scoring
Dermatopathological analysis was performed by a board-certified
dermatopathologist (K.K.). H&E staining was used for orientation
within the sample. With CD3, both peritumoral and intratumorallymphocytes (infiltration) were graded using a semiquantitative
approach defining both intra- and peritumoral lymphocytes as absent/
mild, moderate, or severe. Special emphasis was on dynamics in
tumor infiltration, especially on increasing lymphocyte infiltration
after systemic treatments. CD3-positive tumor-infiltrating lympho-
cytes were used as a surrogate for TIL. IDO expression on high
endothelial venules was assessed by I.C. as absent, focally positive, or
positive. PDL1 expression on tumor cells was quantified by Mosaic
Laboratories, Lake Forest, CA (on behalf of BMS). A cutoff of 1%
positive tumor cells was used [19].
Expression of T-Cell–Associated Genes from TCGA
To confirm the prognostic relevance of T-cell–associated genes in
melanoma, analysis of RNAseq data from the TCGA melanoma data
set was used using an online tool [15]. T-cell marker expression
including immune checkpoints, melanoma, and fibroblast specific
genes were assessed. A comparison of overall survival comparing the
top 10% to the bottom 10%, as well as the top 25% and bottom 25%
expression groups was performed. The log-rank test was used to test
for significant survival difference; a P value less than .05 was
considered as statistically significant.
Results
Biopsy Locations
In total, paired tissue samples of metastases of 43 patients (for
detailed description of the patient population, see Table 1) were
available for definitive histological and clinical evaluation. Most
pretreatment metastases were subcutaneous (n = 29) or nodal (n = 8)
along with lung (n = 2), soft tissue (n = 2), liver (n = 1), and one
metastasis of unknown origin (n = 1). Posttreatment metastases
originated from similar locations (subcutaneous (n = 31), followed by
nodal (n = 5), soft tissue (n = 4), bone (n = 1), ileum (n = 1), and
cerebral (n = 1) (Table 1).
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Types of the primary cutaneous melanoma included nodular (n =
15), superficial spreading (n = 10), unknown type (n = 8),
acral-lentiginous (n = 4), amelanotic (n = 3), and nevoid (n = 1).
In two patients, metastatic melanoma of unknown origin was
diagnosed (n = 2) (Table 1).Treatments
During the time between the biopsies, 10 patients underwent
immunotherapies, including ipilimumab (n = 8) and pembrolizumab
(n = 2); 18 patients underwent targeted therapy, including BRAF
inhibitors (vemurafenib) (n = 12), MEK inhibitors (binimetinib,
selumetinib, n = 5), and a combination of both (n = 1); 6 patients
received sequential combinations of targeted and immunotherapy; 2 had
sequential combinations of immunotherapy and other therapies
(including chemotherapy); and 1 had all three treatment types (Table 1).IDO Immunoreactivity on Peritumoral Endothelium Cells
Pretreatment samples presented IDO immunoreactivity in 17 out
of 43 patients (39.53%) versus 25 (58.14%) IDO-negative with IDO
status not evaluable due to technical reasons in one sample. After
treatments, IDO-positive samples decreased slightly to 14 (32.56%),
whereas IDO-negative samples increased to 28 (65.12%), with one
sample not being evaluable (Table 2).
Of the patients with only targeted therapy, 12 out of 18 (66.67%)
showed consistent expression levels during treatment, 2 (11.11%)
increased (Figure 1), and 4 (22.22%) decreased. With immunother-
apy only, a decrease was observed in 2 out of 10 (25%), whereas 8
(75%) remained stable. Patients treated with both drugs (n = 6)
remained stable (n = 5, 83.33%), and one patient (16.67%) showed
increased IDO expression. In a subset of patients treated with other
treatment types (n = 6), 1 (16.67%) increased, 2 (33.33%)
decreased, and 3 (50%) stable cases were seen. Furthermore, one
patient who received all treatment types remained stable.
Of 43 patients, we observed a decrease in IDO positivity under
treatment in 8 (18.60%) patients, whereas we observed an increase in 5
(11.63%) of patients, while 30 (69.77%) patients displayed constant IDO
status.Table 2. Evaluation of TIL, PD-L1, and IDO1 before and after Therapy
TIL Infiltration Before TIL Infiltration After
Moderate or severe 15 Moderate or severe 16
Less 25 Less 24
NA 3 NA 3
IDO1 before IDO1 after
Yes 17 Yes 14
No 25 No 28
NA 1 NA 1
PDL1 (N1%) before PDL1 (N1%) after
Yes 7 Yes 15
No 32 No 25
NA 4 NA 3
IDO1 and PDL1 positivity before IDO1 and PDL1 positivity after
Double negative 19 Double negative 17
IDO1 positive 13 IDO1 positive 7
PDL1 positive 3 PDL1 positive 8
Double positive 4 Double positive 7TILs
Out of 18 patients treated with targeted therapy only, 7 (38.89%)
patients display increasing TILs.
No increase in TILs was observed in 9 (50%), and 2 (11.11%)
were not amenable to complete evaluation. Ten patients were treated
with only immunotherapies, and increasing TILs are seen in 4 (40%)
patients versus 5 (50%) patients with stable infiltration, and 1 patient
that could not be completely evaluated. In 7 patients with different
regimens including other treatment types than targeted and
immunotherapy, 3 (42.86%) patients display an increase in staining.
Increasing tumor infiltrating lymphocytes are observed in 1 (16.67%)
out of 6 patients treated with both immunotherapy and targeted
therapy (Table 2).PDL1
At baseline, PDL1 is expressed on more than 1% of tumor cells in
7 (16.28%) versus 15 (34.88%) samples. Four samples before and 3
samples after treatment were not evaluable; 32 (74.42%) pretreat-
ment and 25 (58.14%) posttreatment display less than 1% of tumor
cells expressing PDL1.
Patients treated with only immunotherapy (n = 10) remained
mostly stable (70%), with 1 (10%) increase and 2 patients not
amenable to complete evaluation (Figure 2A). Out of 18 patients with
only targeted therapy, 10 (55.56%) displayed stable expression, 6
(33.33%) increased, and 2 were not amenable to complete evaluation
(Figures 2B and 3).
After both targeted and immunotherapy (n = 6), an increase was
observed in 1 (16.66%) case, 4 (66.66%) remained stable, and 1
(16.66%) was not amenable to evaluation. In 9 patients treated also
with other treatment types, an increase was seen in 1 (11.11%)
patient, decreases were seen in 2 (22.22%), 5 (55.56%) remained
stable, and 1 (11.11%) patient was not amenable to complete
evaluation (Table 2).
Coexpression of IDO1, PDL1, and TILs
Investigating IDO, PDL1, and TIL coexpression before treatment,
2 (5.56%) were triple positive, 2 (5.56%) were IDO1 and PDL1
double positive, 1 (2.78%) was PD-L1 and CD3 double positive, 6
(16.67%) were CD3 and IDO1 double positive, 1 (2.78%) was only
PDL1 positive, 6 (16.67%) were only IDO1 positive, 11 (30.56%)
were only CD3 positive, and 7 (19.44%) were negative for all markers
(Figure 4A). After treatment, 4 (11.11%) were triple positive, 3
(8.33%) were IDO1 and PDL1 double positive, 6 (16.67%) were
PD-L1 and CD3 double positive, 5 (13.89%) were CD3 and IDO1
double positive, 1 (2.78%) was only PDL1 positive, 2 (5.56%) were
only IDO1 positive, 5 (13.89%) were only CD3 positive, and 10
(27.78%) were negative for all markers (Figure 4B).In Silico Analysis of the TCGA Data Set
As our patient cohort was quite small, we used the TCGA to
determine if significant differences in the overall survival of patients
were associatedwith the expression of every T-cell specific gene assessed.
At 25% expression levels which include 114 patients in each cohort,
these includeCD3G (5.28 vs 1.37 years, P b .0001) (Figure 5),CD8A
(5.54 vs 1.34 years, P b .0001), CTLA4 (5.68 vs 1.7 years,
P N .0001), CD274 (10.45 vs 1.29 years, P b .0001), PDCD1 (5.68
vs 1.28 years, P b .0001), and even IDO1 (5.54 vs 1.69 years,
P b .0001).
Before MEKi After MEKi
HE
IDO1
A
HE
IDO1
B
4X
10X Before MEKi After MEKi
Figure 1. Example of IDO1 expression increasing after targeted therapy. (A) Histology of HE and IDO1 staining at 4× magnification of a
patient before and after MEK inhibitor treatment. IDO1 staining was evaluated in the endothelial cells. (B) Histology of HE and IDO1
staining at 10× magnification of a patient before and after MEK inhibitor treatment. IDO1 staining was evaluated in the endothelial cells.
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commonly overexpressed in melanoma cells including MLANA,
CDKN2B, BRAF, NRAS, and MITF, all of which did not
demonstrate any significant difference in median survival. However,
for S100B, a significant (P = .014) difference of median survival of
3.19 years in the top 25% expression versus 1.87 years in the bottom
25% expression group was found.
When looking at PDGFRA and VIM, which are commonly
expressed in fibroblasts, no survival difference was observed.Discussion
Immunotherapeutic strategies are evolving rapidly. Within the next
years, several treatment options including anti-CTLA4, PD1, PDL1,
Lag-3, IDO inhibitors, and others may be available. Anti-PD1therapy today is the backbone of IT. Our data for the first time
demonstrate a clinical relevance of an immune marker assessed by
immunohistochemistry. Based on ongoing translational research,
other biomarkers appear promising such as LAG 3 expression [20],
IDO expression, or genetic information (eg, mutational burden).
In the near future, it will be challenging to rationally establish
treatment sequences of combinations of drugs. Biomarkers should be
able to support clinical decision making and ideally should be the
basis for precision immunotherapy. First steps in this direction
include the immunoscore approach, PDL1 immunoreactivity, and
immune signatures [21].
However, there is still limited information concerning the
longitudinal consistency of immune markers such as PDL1 and the
correlation with other immunological features such as the intratu-
moral presence of T-cells and the expression of IDO1.
Figure 2. The evolution of PDL1 immunoreactivity in IT (A) versus TT (B) patients demonstrating more increases in the TT population. (A)
Sankey plot showing changes of PDL1 expression levels in patients treated with immunotherapy. (B) Sankey plot showing changes of
PDL1 expression levels in patients treated with targeted therapy.
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immunorelevant tissue markers that might be important for
immunotherapy of metastatic melanoma. We have focused on
patients with multiple biopsies and, in addition, used expression data
of TCGA to describe the relevance of several immune markers in an
independent data set.
The analyses of the TCGA have shown that all T-cell specific genes
such as CD3, CD8, CTLA4, CD274, PD-1, and IDO1 are
expressed at higher levels in patients with a prolonged overall
survival. This means that any molecule analyzed that is associatedwith the presence of T-cells implies a better outcome, which is
consistent with the published literature about the association of TILs
with good prognosis.
We investigated metastatic tissues of 43 melanoma patients, which
allowed us to compare both pre- and posttreatment lesions.
We were interested in staining for IDO1, the presence of T-cells
infiltrates, and PDL1. Concerning TILs, we were especially interested
in the CD3+, CD8+ T-cell population. This population may be the
most important effector population during regression of melanoma
metastasis [22].
Before BRAFi/MEKi After BRAFi/MEKi
HE
PDL1
4X
Before BRAFi/MEKi After BRAFi/MEKi
HE
PDL1
10X
Figure 3. Example of PDL1 expression increasing after targeted therapy. (A) Histology of HE and PDL1 staining at 4× magnification of a
patient before and after combination BRAF and MEK inhibitor treatment. PDL1 staining was evaluated in the tumor cells. (B) Histology of
HE and PDL1 staining at 10× magnification of a patient before and after combination BRAF and MEK inhibitor treatment. PDL1 staining
was evaluated in the tumor cells.
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expression at this site was reported to be of prognostic relevance in
melanoma [10].
Our investigation revealed a number of interesting and highly
relevant results. First, there is considerable inconsistency in the
intraindividual and interindividual expression levels of the immune
markers investigated with a limited overlap before therapy that evolves
into high overlap after treatment. The type of treatment does not
uniformly govern the immune marker expression. However, targeted
therapy seems to upregulate PDL-1 more consistently than IT, which
might favor sequential TT-IT or concomitant therapies.
Since IDO1 und PDL1 are both regulated by interferon gamma,
we were especially interested in the frequency of biopsies that showed
divergent expression. Actually, we were able to show that a number of
biopsies show expression of a single marker only. One might speculate
that the simultaneous presence of both markers might be predictivefor a high response rate using IDO inhibitors and anti-PD1 combo
treatments.
In conclusion, we demonstrate that simultaneous immunohisto-
chemistry for IDO1 and PDL1 and the presence of TILs identify
patients with various immune marker combinations. Theoretically,
this investigation might help to select patients for specific IT
approaches. The repeated use of these immune parameters together
with others, for example, LAG-3 expression, will be helpful to
develop precision immunotherapy in the near future [23]. Since IDO
is the target for several new medications in clinical trials today, IDO
expression on endothelial cells must be studied as a biomarker in the
context of these clinical trials.
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